TOPICAL TREATMENT USING ANTIHISTAMINIC, STEROID AND A COMBINATION OF BOTH IN ALLERGIC RHINITIS-A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL

被引:2
|
作者
Havle, Abhay D. [1 ]
Pincha, Naman [1 ]
Prabhune, Sanket C. [1 ]
机构
[1] Krishna Inst Med Sci Deemed Be Univ, Dept Otorhinolaryngol, Karad 415110, Maharashtra, India
来源
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH | 2020年 / 11卷 / 04期
关键词
Azelastine; Eosinophils; Fluticasone; Symptom assessment; FLUTICASONE PROPIONATE; NASAL SPRAY; AZELASTINE;
D O I
10.13040/IJPSR.0975-8232.11(4).1917-21
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study evaluates the effectiveness of corticosteroid fluticasone propionate, antihistaminic azelastine, and a combination of both as well as to find out the prognostic significance of absolute eosinophil count (AEC) in the topical treatment of allergic rhinitis. All cases presenting with symptoms of nasal allergy were included maintaining double-blind status. A total of 225 participants of groups I, II and III were treated with topical azelastine, fluticasone propionate and combination of both. The individual symptom score was recorded before and after treatment at the end of four weeks with the help of symptom evaluation scale. The effectiveness of group-specific drugs was evaluated by comparing individual and total symptom scores. AEC was repeated at the end of four weeks in all cases. After intervention the reduction of total symptom score (TSS) and AEC was 9.26 +/- 0.01, 11.73 +/- 0.54. 11.08 +/- 1.61 and 205.59 +/- 81.18, 176.05 +/- 38.23, 195.75 + 29.22 in group I, II and III respectively. Similarly for sneezing it was 0.21 +/- 0.41. 0.24 +/- 0.43 and 0.13 +/- 0.38, for nasal obstruction 0.4 +/- 0.57. 0.08 +/- 0.13 and 0.33 +/- 0.6, for nasal discharge 0.72 +/- 0.83. 0.04 +/- 0.20 and 0.21 +/- 0.41 and for nasal itching 0.11 +/- 0.39. 0.04 +/- 0.20 and 0.25 +/- 0.44 in group I, II and III respectively. Fluticasone propionate (interventional agent of group II) was found to be the most efficacious in reducing TSS (95.52%). AEC (79.82%). and all individual symptom scores except in case of a symptom of sneezing. the combination of azelastine and fluticasone propionate (interventional agent of group III) was most efficacious and statistically significant.
引用
收藏
页码:1917 / 1921
页数:5
相关论文
共 50 条
  • [21] Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial
    Bager, Peter
    Arnved, John
    Ronborg, Steen
    Wohlfahrt, Jan
    Poulsen, Lars K.
    Westergaard, Tine
    Petersen, Henning Willads
    Kristensen, Bjarne
    Thamsborg, Stig
    Roepstorff, Allan
    Kapel, Christian
    Melbye, Mads
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (01) : 123 - 130
  • [22] Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial
    Zhang, Junyan
    Yang, Xiaobin
    Chen, Guangui
    Hu, Jintao
    He, Ying
    Ma, Jinxiang
    Ma, Zhaoen
    Chen, Huifang
    Huang, Yuyi
    Wu, Qiurong
    Liu, Yongping
    Yu, Lu
    Zhang, Hong
    Lai, He
    Zhang, Jianguo
    Zhai, Jinming
    Huang, Minqi
    Zou, Zehong
    Tao, Ailin
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 132 (03) : 346 - 354.e1
  • [23] TREATMENT OF CHRONIC PERENNIAL ALLERGIC RHINITIS - DOUBLE-BLIND TRIAL OF CROMOLYN SODIUM
    MCDOWELL, MK
    SPITZ, E
    ANNALS OF ALLERGY, 1977, 39 (03): : 169 - 174
  • [24] DOUBLE-BLIND TRIAL OF A HEATED NASAL AEROSOL IN THE TREATMENT OF PERENNIAL ALLERGIC RHINITIS
    OPPENHEIMER, J
    BUCHMEIER, A
    NELSON, HS
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 92 (01) : 56 - 60
  • [25] A DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF INTERVENT BEDDING SYSTEM IN PERENNIAL ALLERGIC RHINITIS
    HOWARTH, PH
    LUNN, A
    TOMKINS, S
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1992, 89 (01) : 305 - 305
  • [26] The efficacy and safety of Yupingfeng Powder with variation in the treatment of allergic rhinitis: Study protocol for a randomized, double-blind, placebo-controlled trial
    Cheong, Pui Kuan
    Ho, Tin Muk
    Chan, Kam Leung
    Lo, Cho Wing
    Leung, Sin Bond
    Hon, Kam Lun
    Leung, Ka Chun
    Siu, Tony Hon Chung
    Song, Tian-He
    Zhang, Hongwei
    Ching, Jessica Yuet Ling
    Chow, Tak Yee
    Sum, Chi Him
    Chia, Chon Pin
    Lin, Zhi-Xiu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [27] A topical microemulsion for the prevention of allergic rhinitis symptoms: results of a randomized, controlled, double-blind, parallel group, multicentre, multinational clinical trial (Nares study)
    Pedro Ojeda
    Núria Piqué
    Alicia Alonso
    Julio Delgado
    Francisco Feo
    Juan Manuel Igea
    Ana Navarro
    José María Olaguibel
    Javier Subiza
    Carles Nieto
    Morgan Andersson
    Allergy, Asthma & Clinical Immunology, 9
  • [28] Double-Blind Placebo-Controlled Trial of Bepotastine Salicylate in Patients With Allergic Rhinitis
    Mo, Ji-Hun
    Jeong, Jin Hyeok
    Kim, Tae Hoon
    Kim, Seon-Tae
    Kim, Soo Whan
    Lee, Kun Hee
    Hong, Seung-No
    Kim, Hyo Yeol
    Kim, Dae Woo
    Kim, Dong-Young
    Kim, Chang-Hoon
    Cho, Seok Hyun
    Rhee, Chae-Seo
    LARYNGOSCOPE, 2021, 131 (03): : E702 - E709
  • [29] DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL
    ENGLISH, PMB
    TITCHEN, AC
    BRITISH JOURNAL OF GENERAL PRACTICE, 1992, 42 (354): : 37 - 38
  • [30] A topical microemulsion for the prevention of allergic rhinitis symptoms: results of a randomized, controlled, double-blind, parallel group, multicentre, multinational clinical trial (Nares study)
    Ojeda, Pedro
    Pique, Nuria
    Alonso, Alicia
    Delgado, Julio
    Feo, Francisco
    Manuel Igea, Juan
    Navarro, Ana
    Maria Olaguibel, Jose
    Subiza, Javier
    Nieto, Carles
    Andersson, Morgan
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2013, 9